LU500037B1 - Fucosyl-disaccharide with Prebiotic Effect, Method for Preparing the Same and Application Thereof - Google Patents
Fucosyl-disaccharide with Prebiotic Effect, Method for Preparing the Same and Application Thereof Download PDFInfo
- Publication number
- LU500037B1 LU500037B1 LU500037A LU500037A LU500037B1 LU 500037 B1 LU500037 B1 LU 500037B1 LU 500037 A LU500037 A LU 500037A LU 500037 A LU500037 A LU 500037A LU 500037 B1 LU500037 B1 LU 500037B1
- Authority
- LU
- Luxembourg
- Prior art keywords
- disaccharide
- fucosyl
- eps
- enterobacter
- fermentation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 15
- 230000000694 effects Effects 0.000 title claims abstract description 12
- 241000588914 Enterobacter Species 0.000 claims abstract description 33
- 238000000855 fermentation Methods 0.000 claims abstract description 29
- 230000004151 fermentation Effects 0.000 claims abstract description 28
- 235000000346 sugar Nutrition 0.000 claims abstract description 13
- 150000004676 glycans Chemical class 0.000 claims abstract description 10
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 10
- 239000005017 polysaccharide Substances 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 230000035755 proliferation Effects 0.000 claims abstract description 8
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 20
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 20
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 18
- 239000006228 supernatant Substances 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000006041 probiotic Substances 0.000 claims description 9
- 235000018291 probiotics Nutrition 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000007836 KH2PO4 Substances 0.000 claims description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 5
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000001888 Peptone Substances 0.000 claims description 4
- 108010080698 Peptones Proteins 0.000 claims description 4
- 235000015278 beef Nutrition 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 235000011148 calcium chloride Nutrition 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 229940041514 candida albicans extract Drugs 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 235000019319 peptone Nutrition 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 4
- 239000012498 ultrapure water Substances 0.000 claims description 4
- 239000012138 yeast extract Substances 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000002054 inoculum Substances 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims 1
- 229910052939 potassium sulfate Inorganic materials 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 abstract description 17
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 16
- 241000702462 Akkermansia muciniphila Species 0.000 abstract description 13
- 241000186000 Bifidobacterium Species 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 150000002016 disaccharides Chemical class 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 17
- 239000002609 medium Substances 0.000 description 16
- SNFSYLYCDAVZGP-OLAZETNGSA-N 2'-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@H](O)[C@@H]1O SNFSYLYCDAVZGP-OLAZETNGSA-N 0.000 description 13
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 description 13
- 150000002772 monosaccharides Chemical class 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 7
- 229940004120 bifidobacterium infantis Drugs 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 6
- 241000186016 Bifidobacterium bifidum Species 0.000 description 6
- 241000186012 Bifidobacterium breve Species 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 4
- 235000013350 formula milk Nutrition 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000010865 sewage Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001551 total correlation spectroscopy Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 229920002444 Exopolysaccharide Polymers 0.000 description 2
- 238000004977 Hueckel calculation Methods 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001977 collision-induced dissociation tandem mass spectrometry Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 229940062827 2'-fucosyllactose Drugs 0.000 description 1
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- -1 fucosyl oligosaccharide Chemical class 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/12—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C13—SUGAR INDUSTRY
- C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
- C13K13/00—Sugars not otherwise provided for in this class
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention discloses fucosyl-disaccharide with prebiotic effect, a method for preparing the same and application thereof, and belongs to the field of oligosaccharide preparation technology. The method has the following specific steps: using liquid fermentation Enterobacter F-CE2 to prepare extracellular polysaccharide (EPS), performing acidolysis on the EPS at high temperature and at high pressure to obtain a degraded sugar solution; performing ultrafiltration on the degraded sugar solution to fractionate and remove undegraded macromolecular sugar fragments, collecting oligosaccharide components with a molecular weight ? 500 Da, lyophilizing the oligosaccharide components to obtain fucosyl-disaccharide. The fucosyl-disaccharide has the following identified structure: ?-D-Glcp-(1?4)-?-L-Fucp and ?-D-Galp-(1?3)-?-L-Fucp. Preparation technology of fucosyl-disaccharide of the present invention has the advantages of simple operation, low cost, easy expansion of production and high yield of disaccharide. The fucosyl-disaccharide obtained in the present invention can promote the proliferation of Akkermansia muciniphila and a plurality of strains of bifidobacteria.
Description
DESCRIPTION Fucosyl-disaccharide with Prebiotic Effect, Method for Preparing the Same and Application Thereof
TECHNICAL FIELD The present invention relates to the field of oligosaccharide preparation technology, and particularly, to a fucosyl-disaccharide with prebiotic effect, a method for preparing the same and application thereof.
BACKGROUND There is a plurality of oligosaccharides (HMOs) in breast milk, among which, 2'-fucosyllactose (2'-FL) is a kind of fucosyl oligosaccharide with the highest content, a variety of functions for newborn infants includes repairing nerves, promoting brain development, improving allergy symptoms, regulating intestinal flora stability, and other functions. With the realization of in vitro synthesis of 2'-FL, clinical studies have also shown that adding 2"-FL into the milk powder can promote the development of brain in infants and young children with good tolerance. Because of the complex synthesis and high price of 2'-FL, many infant formula milk powders have been added with galacto-oligosaccharide and fructo- oligosaccharide with functions similar to HMOs. However, the structures of these oligosaccharides are different from 2'-FL and have different health benefits. Currently, it is of great significance to find the fucose-containing oligosaccharides
(FCOs) that has the similar structure and functions with 2’-FL and can be produced in large quantities.
Akkermansia muciniphila is a strictly anaerobic intestinal bacterium isolated from human feces in recent years, which is closely related to the health of the human body. The relative abundance of the Akkermansia muciniphila is negatively correlated with a plurality of diseases including inflammatory bowel disease, appendicitis, obesity, type 2 diabetes, and adolescent autism. In 1899, bifidobacteria was firstly isolated from infant stool by French scientist Dr. Tisser. The health of infant is closely related to the presence and quantity of bifidobacteria in the body. The number of bifidobacteria in intestines of breast-fed infants is much greater than that of infants fed with a milk powder, and breast milk oligosaccharide plays an important role in it. Furthermore, short-chain fatty acids, the metabolites of the Akkermansia muciniphila and bifidobacteria, can also be used as energy sources for intestinal epithelial cells to promote the proliferation of intestinal epitheliacells, and thereby improve intestinal tissues. Various studies have shown that FCOs can be metabolized by the Akkermansia muciniphila and the bifidobacteria. The supplement of FCOs in food or fodders can work as prebiotics to help regulate intestinal microbiota of humans or animals.
Most of the existing FCOs are prepared from fucoidan derived from brown algae or sea cucumbers using acidolysis or enzymatic hydrolysis, however, the preparation method possesses low yield rates and high costs, further, the degradation product has a large molecular weight and is difficult to be quickly utilized by probiotics. Preparation of bacterial extracellular polysaccharide (EPS) has extensive research and development value for its advantages of being weak- influenced by the surroundings, a short cycle, high yield, etc. In recent years, it has been reported that fucose-containing EPS can be prepared by the fermentation of specific strains, such as Enterobacter A47, Bacillus licheniformis BioE-BL11, and Michigan corynebacteria Cm542 and so on. However, bacterial exopolysaccharide has a high molecular weight and high viscosity, and hence cannot be effectively degraded and utilized by probiotics which limit its application of functional activities. Therefore, using a suitable method to degrade fucose-rich EPS with high molecular weight into FCOs with lower molecular weight can effectively increase the utilization value of EPS while providing new technical means for the industrial production of new FCOs.
SUMMARY The objective of the present invention is to provide fucosyl-disaccharide with prebiotic effect, a method for preparing the same and application thereof, so as to solve the forgoing problems in the prior art.
The present invention provides fucosyl-disaccharide with prebiotic effect, wherein the fucosyl-disaccharide has structure of B-D-Glcp-(1—4)-B-L-Fucp and a-D-Galp- (1—3)-B-L-Fucp.
The present invention provides a method for preparing fucosyl-disaccharide with prebiotic effect, specifically including the following steps: (1) fermenting Enterobacter F-CE2 to extract EPS; (2) preparing a solution with the EPS obtained in step (1) and performing acidolysis for the EPS at high temperature and at high pressure to obtain a degraded sugar solution; (3) performing ultrafiltration for the degraded sugar solution obtained in step (2) to remove undegraded macromolecular sugars, and then lyophilizing the obtained filtrate solution to obtain the fucosyl-disaccharide.
Further, the Enterobacter F-CE2 of step (1) has a preservation number of CGMCC No. 20359, was preserved on July 14, 2020 in China General Microbiological Culture Collection Center, No. 3, 1% Yard, Beichen West Road, Chaoyang District, Beijing. The EPS of Enterobacter F-CE2 presents a mole ratio of 30%-45% of fucose.
Further, a specific preparation method of the EPS in step (1) includes: after the third activation of Enterobacter F-CE2 , the Enterobacter F-CE2 is inoculated into a fermentation medium; after shaking and fermentation, a resulting fermentation broth is centrifuged at 6000 r/min for 15 min to collect a supernatant; the resulting supernatant is rotated, evaporated and concentrated; after the concentration, the supernatant is precipitated with three times volume of 95% ethanol to precipitate the EPS, and the EPS is collected, then dissolved in ultrapure water, dialyzed in a dialysis bag for 48 h and then vacuum-dried.
Further, the fermentation medium has the following formula: beef extract of 5-15 g/L, yeast extract of 2~6 g/L, peptone of 10-20 g/L, glucose of 20-40 g/L, NH4Cl of 0.3 g/L, KCl of 1 g/L, (NHa)2SO4 of 0.3 g/L, NazHPO4 of 10 g/L, KH2PO4 of 3 g/L, KSO4 of 1 g/L, NaCl of 1 g/L, MgSO4 °7H20 of 0.2 g/L, CaCl2*6H20 of
0.02 g/L, and FeSO4 of 0.001 g/L, pH is 7.0~7.2.
Further, the fermentation medium has inoculum volume of 0.1% to 1% (V/V), fermentation temperature of 27 °C to 38 °C, shaking speed of 120 r/min~180 r/min, and fermentation time of 24 h~72 h.
Further, high-pressure and high-temperature specific conditions of step (2) are as follows: pressure is 0.1~0.3 Mpa and temperature is 130~150 °C.
Further, an EPS solution in step (2) has the following conditions for acid treatment: adding hydrochloric acid to the EPS solution, and adjusting pH to 2~4, with treating time of 2 to 5 h, and concentration of 10 to 50 mg/ml EPS.
Further, the degraded sugar solution obtained by ultrafiltration in step (3) has a molecular weight of less than or equal to 500 Da.
The present invention further provides an application of fucosyl-disaccharide in promoting the proliferation of probiotics.
The present invention discloses the following technical effects: Fucosyl-disaccharide preparation technology of the present invention has the advantages of simple operation, low cost, easy expansion of production and high yield of the fucosyl-disaccharide.
The fucosyl-disaccharide provided by the present invention has a novel structure, high purity and high yield, can be fermented and utilized by intestinal probiotics, can reduce the pH value of intestinal environment, can promote proliferation of Akkermansia muciniphila and a plurality of bifidobacteria strains including Bifidobacterium infantis, and has broad application prospects as new prebiotics.
DESCRIPTION OF THE FIGURES FIG.1 shows a Gram Staining microscopic view of Enterobacter in Embodiment 1; FIG.2 shows an infrared spectrum of Enterobacter EPS in Embodiment 3; FIG.3 shows a GPC view of the molecular weight of Enterobacter EPS in Embodiment 3; FIG.4 shows a high performance liquid chromatography (HPLC) chromatogram of monosaccharide compositions of FCOs in Embodiment 5;
FIG.5 shows a mass spectrum of FCOs in Embodiment 5; FIG.5-A shows an electrospray lonization-mass spectrometry (ESI-MS) spectra in positive ion mode, and FIG.5-B shows an ESI-CID (collision-induced dissociation) -MS/MS spectra in positive ion mode;
FIG.6 shows a 1D 'H nuclear magnetic resonance (NMR) spectrum of fucosyl- disaccharide in Embodiment 5;
FIG.7 shows a 1D '3C NMR spectrum of fucosyl-disaccharide in Embodiment 5;
FIG.8 shows a 2D NMR 'H -'H TOCSY spectrum of fucosyl-disaccharide in Embodiment 5;
FIG. 9 shows a 2D NMR 'H -3C HSQC spectrum fucosyl-disaccharide in Embodiment 5;
FIG.10 shows 2D NMR 'H -3C HMBC spectrum of fucosyl-disaccharide in Embodiment 5;
FI1G.11 shows the promoting effect of fucosyl-disaccharide and 2'-FL prebiotic on the proliferation ability- and acid-producing ability of four probiotics strains of Embodiment 6, FIG.11-A shows Bifidobacterium breve, FIG.11-B shows Bifidobacterium infantis, FIG.11-C shows Bifidobacterium bifidum, and FIG.11-D shows Akkermansia muciniphila;
FIG. 12 shows promotion of fucosyl-disaccharide and 2'-FL prebiotics on short-chain fatty acids production of four probiotics strains of Embodiment 6, F1G.12-A shows Bifidobacterium breve, F1G.12-B shows Bifidobacterium infantis, FIG.12-C shows Bifidobacterium bifidum, and FIG.12-D shows Akkermansia muciniphila.
DESCRIPTION OF THE INVENTION The embodiments of the present invention are further described below in conjunction with the figures. The detailed description should not be considered as a limitation to the present invention, but should be understood as a more detailed description of certain aspects, characteristics and embodiments of the present invention.
It should be understood that the terms described in the present invention are only used to describe specific embodiments and are not used to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between an upper limit and a lower limit of the range is also specifically disclosed. Each smaller range between an intermediate value within any stated value or a stated range and an intermediate value within any other stated value or the stated range is also included in the present invention. Upper and lower limits of these smaller ranges can be independently included or excluded from the range.
Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by the person skilled in the art in the field of the present invention. Although the present invention only describes preferred methods and materials, any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe methods and/or materials related to the documents. In case of conflict with any incorporated document, the contents of this manual shall prevail.
Without departing from the scope or spirit of the present invention, it is obvious to the person skilled in the art that various improvements and changes can be made to the specific embodiments of the present specification. Other embodiments derived from the specification of the present invention will be obvious to the person skilled in the art. The specification and embodiments of this application are only exemplary.
As used herein, "comprise", "include", "have", "contain", etc., are all open terms, which means including but not limited thereto.
Embodiment 1: Screening and identification of Enterobacter Sewage samples were collected from a sewage treatment plant in Shinan District, Qingdao City, Shandong Province. Sewage sample (30mL) was collected and centrifuged at 8000 r/min for 20 min at 4 °C. The deposit was re-suspended by using an appropriate amount of PBS solution, and coated on a nutrient agar plate by a coating method, and incubated at 37 °C overnight. After cultivation, 20 single bacterial colonies were picked from the plate, and numbered from 1$-to 20". The 20 single bacterial colonies were enriched using LB liquid medium, respectively, and cultivated at 37 °C for 24 h.
The DNA samples of 20 bacteria was extracted according to the method of a bacterial genome extraction kit. The DNA was used as a template. 16S rDNA universal primer 27F (shown in SEQ ID NO. 1) of 5" AGAGTTTGATCCTGGCTCAG-3' and 1492R (shown in SEQ ID No. 2) of 5" ATTACCGCGGCTGCTGGC-3' were used for colony PCR. The PCR reaction system are as follows: 8 uL Tag enzyme, 10 pL sterile water, 0.5 uL each primer, and 1 pL template. PCR reaction conditions are as follows: (1) pre-denaturation at 95 °C for 5 min; (2) denaturation at 95 °C for 30 s, annealing at 52 °C for 45 s, extension at 72 °C for 2 min, a total of 32 cycles; and (3) re-extension at 72 °C for 1 min. After amplification was ended, PCR amplified products were sent to a biological company for sequencing. Sequencing results were compared by Blast. The results showed that one strain was Enterobacter. The sequencing results were shown as SEQ ID NO. 3, and the microscopic examination results also showed that these bacteria were Gram-negative bacteria in shape of bacilli, as shown in
FIG.1, that is, enterobacteria that were successfully isolated from the sewage. This Enterobacter was named Enterobacter F-CE2 and preserved in China General Microbiological Culture Collection Center, No. 3, 1% Yard, Beichen West Road, Chaoyang District, Beijing, and had a preservation number of CGMCC No. 20359 and a preservation date of July 14, 2020.
Embodiment 2: The optimization of preparation conditions of Enterobacter exopolysaccharide After Enterobacter F-CE2 was activated with a LB liquid medium for three generations, the Enterobacter F-CE2 was inoculated into a liquid fermentation medium with inoculation amount of 0.5% (V/V). The medium was placed in a shaker for shaking and culture at 32° C with rotation speed of 150 r/min for 48 h. After fermentation, the fermentation broth was centrifuged at 6000 r/min for 15 min to remove bacterial precipitates and collect the supernatant. The supernatant was rotated and evaporated to the volume of 1/5 of the initial volume in a rotary evaporator at 50 °C. Then supernatant was precipitated with 3 times volume of 95% ethanol, and let it stand for 4 h. Precipitates were collected after centrifugation at 6000 r/min for 10 min. The precipitates were redissolved with ultrapure water, dialyzed in a 10 kDa dialysis bag for 48 h, and lyophilized in vacuum. Yield of EPS was calculated. The EPS were pre-treated by a PMP (1-phenyl-3-methyl-5- pyrazolone) pre-column derivatization method, and then performed with HPLC of monosaccharide compositions. Fucose content was calculated. Results showed that Enterobacter EPS had a yield of 3~6.5 g/L, and fucose in the EPS had a molar ratio of 30%-45% (see Tables 2 and 4).
The specific operation method of HPLC was as follows: Sample of 5 mg was accurately weighed and placed in an ampoule tube, and 1 mL of trifluoroacetic acid (TFA) with concentration of 2 mol/L was added. The tube was sealed and placed in an oven for hydrolysis at temperature of 110 °C for 6 h. The hydrolyzed sample was evaporated and concentrated, and was redissolved using methanol for several times to remove TFA. A mixed standard monosaccharides sample was prepared in an equimolar ratio and was derived with PMP along with the acidolysis products of oligosaccharide sample. A derivation method was as follows: taking 100 pL of a sample mixture solution to be tested and mixing with 210 pL of 0.3 mol/L NaOH solution, adding 200 pL of 0.5 mol/L PMP solution (dissolved in methanol), mixing the solution evenly, placing the mixture in 70 °C oven and reacting for 60 min; after the reaction, cooling at room temperature for 10 min, and adding 210 pL of 0.3 mol/L HCI to neutralize the excessive alkali. The mixed solution was added with 3 mL of dichloromethane, and was shaken and let it stand. The lower layer was discarded after the mixed solution was layered. The extraction process was repeated for 3 times. The aqueous phase was filtered with a 0.22 um microporous membrane and then analyzed by HPLC method.
HPLC instrument: Agilent 1260 high performance liquid chromatograph; UV detector (245 nm) HPLC column model: Agilent ZORBAX 300 XDB-C18 HPLC conditions: 0.05 mol/L KH2PO4 phosphate buffer (pH 6.7) / CH3CN (83:17, V:V) was used as a mobile phase; the column temperature was 35°C; the flow rate was 1 mL/min; and the sample volume was 20 pL.
The liquid fermentation medium was shown in Table 1 below: Table 1 Beef extract Yeast extract Inorganic (g/L) (g/L) Peptone (g/L) Glucose (g/L) salt © 5 6 10 30 V © 10 6 10 30 V ©) 15 6 10 30 V © 10 2 10 30 V © 10 4 10 30 V ® 10 6 20 30 V D 10 6 15 30 V 6 10 20 V © 10 6 10 40 V Inorganic salt formula were as follows: NH4CI of 0.3 g/L, KCI of 1 g/L, (NH4)2S04 of 0.3 g/L, NazHPO4 of 10g/L, KH2PO4 of 3 g/L, KoSO4 of 1 g/L, NaCl of 1 g/L, MgSO4* 7H20 of 0.2 g/L, CaCl2+6H20 of 0.02 g/L, and FeSO4 of 0.001 g/L. The pH of the medium was adjusted to 7.0~7.2.
Table 2 showed the yields and the fucose contents of Enterobacter EPS prepared using different fermentation media in Embodiment 2. Table 2 Medium © ©@ © @ © © © 6 © EPS yield (g/L) 4.5 65 65 48 5.4 5.8 6.5 3 6.5 Fucose content 43.13 45 45 3874 4054 3994 4429 302 4265 (% mol) Table 3 showed the optimizing culture condition parameters of fermentation medium of Enterobacter: Table 3 Temperature C Rotation Speed r/min Time h © 27 150 48 © 32 150 48 ©) 38 150 48 © 32 120 48 © 32 180 48 © 32 150 24 D 32 150 72 Table 4 showed the yields and fucose content of Enterobacter EPS prepared under different fermentation and culture conditions in Embodiment 2 Table 4 Culture conditions © © ©) © © © © EPS yield (g/L) 5.9 65 55 6.3 6.3 4.1 6.4 Fucose content (%mol) 45 45 4327 4418 4416 4237 4428 Embodiment 3: Determination of basic properties of EPS According to Embodiment 2, conditions of Enterobacter fermentation medium were optimized, and culture conditions with the highest EPS yield and fucose content were selected. The final medium formula was set as follows: beef extract of 10 g/L, yeast extract of 6 g/L, peptone of 10 g/ L, glucose of 30 g/L, NH4Cl of
0.3 g/L, KCI of 1 g/L, (NH4)2SQO4 of 0.3 g/L, Na:HPO4 of 10 g/L, KH2PO4 of 3 g/L, K25SO4 of 1 g/L, NaCl of 1 g /L, MgSO4+7H20 of 0.2g/L, CaCl2*6H20 of 0.02 g/L, and FeSO, of 0.001 g/L. The pH of the medium was adjusted to 7.0~7.2. The medium was incubated at 32 °C and speed of 150 r/min for 48 h. As shown in Table 5, monosaccharide compositions of EPS prepared under optimal conditions included the fucose, glucose, galactose, glucuronic acid, galacturonic acid, mannose, and rhamnose, among which the fucose has mole ratio of about 45.02%.
Table 5 showed a molar ratio of monosaccharide compositions of EPS in Embodiment 3 Table 5 Monosaccharide Mol% Fucose 45.02% + 0.01 Glucose 20.91% + 0.01 Galactose 22.69% + 0.04 Glucuronic acid 4.09% + 0.04 Galacturonic acid 3.71% + 0.03 Mannose 1.86% + 0.03 Rhamnose 1.12% + 0.01 In this experiment, a KBr tablet method was used to measure the sample by infrared spectroscopy. The sample has the following processing method: based on the mass ratio 1:200 of the sample to KBr, about 2-3 Mg sample and 100-600 mg KBr were weighed, transferred to an agate mortar and ground evenly into a powder. The ground powder was transferred to a film-making mold and was placed under pressure of 10 tons for 2 min. After removing the pressure, the piece was taken for the next test. The prepared test piece was visually inspected to be transparent. The test piece was taken out and loaded into a sample holder for infrared spectroscopy analysis, and the model of used instrument was Nicolet Nexus 470 infrared spectrometer. As shown in FIG.2, FIG.2 showed a view of infrared spectrum of Enterobacter EPS. It can be seen that the sample had characteristic absorption peaks at 3427.69, 2926.56, 1639.69, and 1404.60 cm, respectively, which were characteristic absorption peaks of stretching and vibration of characteristic absorption peaks produced by stretching and vibration of O-H, C-H, C=0, and C-O of the polysaccharide. The absorption peaks at 1067.13 cm! and
1026.77 cm indicated the presence of pyranose in polysaccharide, which indicated that the polysaccharide has a carboxyl structure. This result was consistent with the results of HPLC which showed the presence of uronic acid.
The molecular weight of EPS was determined by HPLC system, a refractive index detector, and a TSK gel G4000 PWXL chromatographic column. The system temperature was set to 35°C. The mobile phase consists of 0.2 mol/L NaNO3 and
0.01 mol/L NaH2PO4 was used. The flow rate was 0.5 mL/min and the sampling volume was 20 pL. Different molecular weight dextran (80, 150, 270, 410 and 670 kDa) were used to draw standard curves. Results were shown in FIG. 3. FIG.3 showed a GPC spectrum of molecular weight of Enterobacter EPS with a peaked at 19.674 min. According to standard curve calculation, the EPS had a molecular weight of 5.2x10° Da.
Embodiment 4: Preparation of FCOs through acidolysis at high temperature and at high pressure Conditions of the acidolysis by high pressure were shown in Table 6. The EPS of Enterobacter F-CE2 was dissolved in ultrapure water to prepare a 1~5% polysaccharide solution. Hydrochloric acid was added to the polysaccharide solution. The pH was adjusted to 2~4, the temperature was 130~150 °C and the pressure was 0.1~0.3 Mpa., Treatment was performed for 2~5 h. The pH was adjusted to 7.0 with 2 mol/L NaOH. The obtained oligosaccharide solution was centrifuged at 5000 r/min for 10 min. Precipitates were dried and weighed, and the supernatant was collected. A dialysis bag with molecular weight cut-off of 500 Da was used to intercept the supernatant to obtain an oligosaccharide sugar solution with a molecular weight of less than 500 Da. The sugar solution was lyophilized into a powder and weighed. Yields of EPS oligosaccharide were shown in Table 7. Results showed that oligosaccharide with a molecular weight of less than 500 Da had a yield of 50%~70% after the acid treatment of Enterobacter EPS in an environment at high temperature and at high pressure. Optimal reaction conditions were as follows: polysaccharide concentration of 30 mg/ml, pH of 3, vacuum degree of 0.2 Mpa and treatment for 4~5 h.
Table 6 showed conditions for acidolysis of Enterobacter EPS at high- pressure in Embodiment 4.
Table 6 Serial Polysaccharide Vacuum Degree ; ; Number Concentration mg/mI pH Mpa Reaction Time h © 10 3 0.2 4 © 30 3 0.2 4 ©) 50 3 0.2 4 © 30 4 0.2 4 © 30 2 0.2 4 © 30 3 0.3 4 D 30 3 0.1 4 3 0.2 2 © 30 3 0.2 5 Table 7 showed yields of acidolysis of Enterobacter EPS oligosaccharide at high-pressure in Embodiment 4.
Table 7 Conditions ® @ ® @ ® ® @ © Yields of66.74% 70.24% 56.61% 68.75% 60.19% 57.24% 70.18% 53.25% 70.24% oligosaccharide Embodiment 5: Analysis of FCOs Structure (1) Analysis for monosaccharide compositions of FCOs Monosaccharide compositions of the FCOs were detected according to the method of HPLC analysis in Embodiment 2. Results were shown in FIG.4. FIG.4 showed a HPLC spectrum of the monosaccharide compositions of FCOs. It can be seen that FCOs consists of glucose, galactose, and fucose, with a ratio of 1:1:2.
(2) Mass spectrometry analysis of FCOs The analysis was performed using Agilent 1290 Infinity || system equipped with Agilent 6460 triple quadrupole mass spectrometer. Positive and negative ion ESI-MS and ESI-CID-MS/MS were used to identify the molecular weight of FCOs. The mobile phase was acetonitrile/water (1:1, V/V), the flow rate was 0.4 mL/min, the atomizer pressure was 40 psi, the capillary voltage was 3500 V, the collision gas was argon, and the collision energy was 10-55 eV. FIG.5 showed mass spectrum results of the oligosaccharides sample; FIG.5-A showed a positive ion mode ESI-MS, and FIG.5-B showed a positive ion mode ESI-CID-MS/MS. It can be seen that the FCO was a fucosyl-disaccharide with a molecular weight of 326 Da. Combined with results of monosaccharide composition, the fucosyl- disaccharide may be a disaccharide consisting of glucose and fucose, or a disaccharide consisting of galactose and fucose.
(3) NMR analysis of FCOs For NMR analysis of FCOs, 10 mg of a fucosyl-disaccharide sample was dissolved in 0.5 mL DO and lyophilized. The sample was then redissolved in 0.5 mL of D2O, and acetone was added to be used as an internal standard for the calibration of chemical shift. All one-dimensional (*H, ‘°C, DEPT90°, 135.) and two- dimensional ('H-'H COSY, "H-H TOCSY, 'H-'*C HSQC, 'H-*C HMBC) NMR spectra were recorded using Agilent DD2-500 spectrometer with frequency of 500MHz at 25°C. FIG.6 to 10 showed the NMR results of fucosyl-disaccharide. FIG.6 shows the 1D 'H NMR spectrum. FIG.7 shows the 1D "°C NMR spectrum.
FIG.8 shows the 2D NMR 'H -'H TOCSY spectrum.
FIG.9 shows the 2D NMR ‘H -13C HSQC spectrum.
FIG.10 shows 2D NMR 'H -*C HMBC spectrum; Table 8 showed chemical shifts of 'H and '*C of each monosaccharide residue of the fucosyl-disaccharide.
The results showed that the fucosyl-disaccharide had a structure of B-D-Glcp-(1—4)-B-L-Fucp and a-D-Galp-(1—3)-B-L-Fucp.
Table 8 showed the 'H and "°C chemical shifts of each monosaccharide residue of fucosyl-disaccharide in Embodiment 5. Table 8 1 2 3 4 5 6 a-D-Galp-(1—3)-B-L-Fucp (a) D-Gal ‘H 5.256 3.798 4.032 3.864 3.491 3.759/3.548 BC 104.01 73.512 70.059 70.896 72.546 62.678 (B)L-Fuc 'H 4.425 3.802 3.503 3.701 23.902 1.275 BC 94.259 70.592 77.896 71.643 68.514 17.321 B-D-Glcp-(1—4)-B-L-Fucp (B)D-Glc IH 4.542 3.526 3.773 3.996 3.543 3.891/3.589 BC 97.928 75.695 77.581 71.090 77.022 64.521 (B)L-Fuc H 4.603 3.512 3.586 3.799 3.856 1.213 13C 103.896 73.546 75.123 81.134 68.409 17.254 Embodiment 6: Probiotic effect of fucosyl-disaccharide In order to explore the probiotic effect of the fucosyl-disaccharide on intestinal microbiota, an experimental process simulated an intestinal anaerobic fermentation environment was used to explored the proliferation effects of the fucosyl-disaccharide on Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium bifidum, and Akkermansia muciniphila, and the substrate utilization efficiency of fucosyl-disaccharide.
Deoxygenated YCFA fermentation medium was used with a single bacteria inoculation amount of 0.5%. Fermentation was conducted at 37 °C for 48 h.
The fermentation products were taken at 0, 12, 24, 36 and 48 h, respectively, for subsequent analysis.
Results were shown in FIG.11. FIG.11 showed the proliferation-promoting effects of fucosyl-disaccharide and 2'-FL prebiotics on four probiotics strains and strain’s acid-producing capacity.
F1G.11-A showed the Bifidobacterium breve.
FIG.11-B showed the Bifidobacterium infantis.
FIG.11-C showed the Bifidobacterium bifidum, and F1G.11-D showed the Akkermansia muciniphila.
Compared with 2'-FL, the fucosyl-disaccharide significantly promoted proliferation of Bifidobacterium breve, Akkermansia muciniphila, Bifidobacterium infantis, and Bifidobacterium bifidum (p<0.05), and the pH value could be reduced within 12 h (reduction by 1 to 2). After the fermentation for 24 h, compared to 2'-FL, the fucosyl-disaccharide can promote bifidobacteria strains to produce more formic acid, acetic acid and lactic acid.
The fucosyl-disaccharide can promote the Akkermansia muciniphila to produce a low level of butyric acid, while 2'-FL cannot.
As shown in FIG.12, FIG.12 showed results of the fucosyl-disaccharide and 2'-FL prebiotics in promoting production of short-chain fatty acids of four probiotics strains.
FIG.12-A showed the Bifidobacterium breve.
FIG.12-B showed the Bifidobacterium infantis.
FIG. 12-C showed the Bifidobacterium bifidum, and FIG.12-D showed the Akkermansia muciniphila.
It should be understood that the person skilled in the art can make improvements or changes based on the above description, and all these improvements and changes should fall within the protection scope of the appended claims of the present invention.
Claims (10)
1.Fucosyl-disaccharide with prebiotic effect, wherein the fucosyl-disaccharide has a structure of B-D-Glcp-(1—4)-B-L-Fucp and a-D-Galp- (1—3)-B-L-Fucp.
2. A method for preparing fucosyl-disaccharide with prebiotic effect according to claim 1, wherein the method specifically comprises the following steps: (1) fermenting Enterobacter F-CE2 to extract extracellular polysaccharide (EPS); (2) preparing a solution with the EPS obtained in step (1) and performing acidolysis for the EPS at high temperature and at high pressure to obtain degraded sugar solution; (3) performing ultrafiltration for the degraded sugar solution obtained in step (2) to remove undegraded macromolecular sugars, and then lyophilizing the obtained filtrate solution to obtain the fucosyl-disaccharide.
3. The method according to claim 2, wherein the Enterobacter F-CE2 of step (1) has a preservation number of CGMCC No. 20359, was preserved on July 14, 2020 in China General Microbiological Culture Collection Center, No. 3, 1% Yard, Beichen West Road, Chaoyang District, Beijing, the Enterobacter F-CE2 has mole ratio of 30%-45% of fucose in the EPS.
4. The method according to claim 2, wherein a specific preparation method of the EPS in step (1) comprises: after the third activation of Enterobacter F-CE2, the Enterobacter F-CE2 is inoculated into a fermentation medium, after shaking and fermentation, a resulting fermentation broth is centrifuged at 6000 r/min for 15 min to collect a supernatant, the resulting supernatant is rotated, evaporated and concentrated, after the concentration, the supernatant is precipitated with three times volume of 95% ethanol to precipitate the EPS, and the EPS is collected, then dissolved in ultrapure water, dialyzed in a dialysis bag for 48 h and then vacuum dried.
5. The method according to claim 4, wherein the fermentation medium has the following formula: beef extract of 5-15 g/L, yeast extract of 2-6 g/L, peptone of 10~20 g/L, glucose of 20- 40 g/L, NH4Cl of 0.3 g/L, KCI of 1 g/L, (NHa)2SO4 of 0.3 g/L, NazHPO4 of 10 g/L, KH2PO4 of 3 g/L, K2SO4 of 1 g/L, NaCl of 1 g/L, M9gSO4 *7H20 of 0.2 g/L, CaCl2*6H20 of 0.02 g/L, and FeSO4 of 0.001 g/L, pH is 7.0~7.2.
6. The method according to claim 4 or 5, wherein the fermentation medium has an inoculum volume of 0.1% to 1% (V/V), fermentation temperature of 27 °C to 38 °C, shaking speed of 120 r/min~180 r/min, and fermentation time of 24 h~72 h.
7. The method according to claim 2, wherein high-pressure and high- temperature specific conditions of step (2) are as follows: the pressure is 0.1~0.3 Mpa and the temperature is 130~150 °C.
8. The method according to claim 2, wherein an EPS solution in step (2) has the following conditions for acidolysis: adding hydrochloric acid to the EPS solution, adjusting pH to 2~4, and having treating time of 2 to 5 h, and concentration of 10 to 50 mg/ml.
9. The method according to claim 2, wherein the molecular weight of the degraded sugar solution obtained by ultrafiltration in step (3) is less than or equal to 500 Da.
10. An application of fucosyl-disaccharide of claim 1 in promoting the proliferation of probiotics.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011447316.7A CN112568445B (en) | 2020-12-09 | 2020-12-09 | Fucoidan with prebiotic effect, and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
LU500037B1 true LU500037B1 (en) | 2021-10-14 |
Family
ID=75131051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU500037A LU500037B1 (en) | 2020-12-09 | 2021-04-14 | Fucosyl-disaccharide with Prebiotic Effect, Method for Preparing the Same and Application Thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112568445B (en) |
LU (1) | LU500037B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115058369B (en) * | 2022-07-20 | 2024-02-20 | 威海迪普森生物科技有限公司 | Preparation method of extracellular polysaccharide-derived fucoidin fermentation synbiotics |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101503720B (en) * | 2009-02-24 | 2011-08-24 | 中国海洋大学 | Preparation of microbial oligosaccharide with prebiotic function |
CN103436640A (en) * | 2013-07-12 | 2013-12-11 | 泰山医学院 | Preparation method for galactooligosaccharide composed of [-->5)beta-D-Galf(1-->] glycosyl |
CN111518711B (en) * | 2019-02-02 | 2021-12-07 | 常熟理工学院 | Enterobacter strain and application thereof in coproduction of microbial exopolysaccharide and 2,3-butanediol |
CN111234047B (en) * | 2020-03-30 | 2021-04-23 | 西南大学 | Exopolysaccharide rich in fucose and preparation method and application thereof |
CN111728976B (en) * | 2020-07-15 | 2021-11-02 | 西南大学 | Application of fucooligosaccharide in preparation of intestinal prebiotics |
CN111808790B (en) * | 2020-06-05 | 2022-02-15 | 武汉中科光谷绿色生物技术有限公司 | Escherichia coli and application thereof in synthesis of fucosylated oligosaccharide |
CN111925995B (en) * | 2020-07-04 | 2022-05-17 | 菲吉乐科(南京)生物科技有限公司 | Microecological preparation prepared by coupling fermentation of bacteriophage and probiotics and preparation method |
-
2020
- 2020-12-09 CN CN202011447316.7A patent/CN112568445B/en active Active
-
2021
- 2021-04-14 LU LU500037A patent/LU500037B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CN112568445A (en) | 2021-03-30 |
CN112568445B (en) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10113145B2 (en) | Paenibacillus sp. strain, cultivation method and use of the same | |
Liu et al. | Isolation, structural characterization and immunological activity of an exopolysaccharide produced by Bacillus licheniformis 8-37-0-1 | |
CN106635924B (en) | Preparation and application of lactobacillus rhamnosus exopolysaccharide | |
AU2011230685B2 (en) | Anti-allergic agent | |
Vijayendra et al. | Physico-chemical characterization of an exopolysaccharide produced by a non-ropy strain of Leuconostoc sp. CFR 2181 isolated from dahi, an Indian traditional lactic fermented milk product | |
KR101851656B1 (en) | Novel Bacillus sonorensis strain capable of producing exopolysaccharide and use of exopolysaccharide | |
US10738275B2 (en) | Paenibacillus sp. strain, cultivation method and use of the same | |
CN112662717A (en) | Lactobacillus rhamnosus exopolysaccharide and preparation method and application thereof | |
Zhang et al. | Characterization and antioxidant activity of released exopolysaccharide from potential probiotic Leuconostoc mesenteroides LM187 | |
CN112662581A (en) | Lactobacillus acidophilus producing extracellular polysaccharide with anti-tumor, blood sugar reducing and blood fat reducing activities and application thereof | |
Li et al. | Structural characterization of exopolysaccharides from Weissella cibaria NC516. 11 in distiller grains and its improvement in gluten-free dough | |
LU500037B1 (en) | Fucosyl-disaccharide with Prebiotic Effect, Method for Preparing the Same and Application Thereof | |
CN114196564B (en) | Tetragenococcus halophilus and application thereof in production of anti-cancer extracellular polysaccharide | |
JP2008245576A (en) | Lactobacillus expectable to have immunomodulating action and extracellular polysaccharide | |
CN104231106B (en) | Paenibacillus exopolysaccharide and preparation method and application of paenibacillus exopolysaccharide | |
CN105147715A (en) | Novel application of neutral extracellular polysaccharides of paecilomyces hepiali | |
Zhou et al. | Production and characterization of exopolysaccharides from salinity-induced Auxenochlorella protothecoides and the analysis of anti-inflammatory activity | |
AU2014378873B2 (en) | Extracellular polysaccharide with immunomodulatory effect and preparation method and use thereof | |
EP1908819B1 (en) | Polysaccharide produced by microorganism belonging to genus bifidobacterium | |
Chen et al. | In vitro prebiotic function of oligosaccharides from Schizophyllum commune and its sulfated derivatives | |
CN116004443B (en) | Lactobacillus delbrueckii, polysaccharide and method for producing extracellular polysaccharide with antioxidant effect and application of lactobacillus delbrueckii, polysaccharide and method | |
CN114134188B (en) | Method for synthesizing extracellular polysaccharide by fermenting wheat bran | |
US20230383323A1 (en) | Bacterial strain for fermenting wheat bran to synthesize extracellular polysaccharide | |
CN113583994B (en) | Preparation method and application of levansucrase | |
CN115895978B (en) | Leuconostoc citricola and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Effective date: 20211014 |